Osteosarcoma Treatment Market Analysis

Osteosarcomas are rare, yet are the leading cause of deaths due to cancer in the pediatric population. It is a high-grade malignancy of mesenchymal origins. They are the most frequent forms of primary bone tumors and account for approximately 20% of all the bone tumors. With the incident population of less than 2500 in the 7MM (the US, EU5 (the UK, Germany, France, Italy, and Spain), and Japan)in 2017, the rarity of Osteosarcomas makes its management quite bone-breaking.

To bridge the treatment gaps, many pharma, and biotech companies in the Osteosarcoma treatment market including EISAI LIMITED, Bayer, Exelixis, Nektar Therapeutics, Y-mAbs Therapeutics, GSK, Novartis, AADi Bioscience, Eleison Pharmaceuticals, Aurorabiopharma, BioAtla, Iovance Biotherapeutics, Bristol Myers Squibb, Cellestia Biotech, among others are developing novel therapeutic strategies.

For more details on Osteosarcoma Treatment Market, visit: https://www.delveinsight.com/blog/osteosarcoma-treatment-market/